Safety of lacosamide in children with refractory partial epilepsy

Pasha, Ismail; Kamate, Mahesh; Suresh, D.K.

doi:10.1016/j.jsps.2015.01.006

Cited by 11 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…62 In a study by Pasha et al, behaviour was evaluated objectively, and was shown to have improved after 3 months' treatment with LCM. 26 A case of a 5-year old girl who developed behavioural problems after taking LCM (100 mg/day for 1 week) was also reported by the same group. 25 After persisting with treatment for 4 weeks, LCM was stopped and the child's behaviour returned to 'normal'.…”

Section: Discussionmentioning

confidence: 68%

“…25 The authors also assessed behaviour using the Conners Comprehensive Behaviour Rating Scale. 26 The score was 48.04 ± 10.57 at baseline and 19.27 ± 8.03 after 3 months' treatment with LCM, representing a statistically significant improvement in behaviour. The significant reduction in seizure frequency during the study may have contributed to the improvement in behaviour.…”

Section: Safety Outcomesmentioning

confidence: 86%

See 1 more Smart Citation

Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy — A systematic review of the literature using lacosamide as an example

Arzimanoglou

Kalilani

Anamoo

et al. 2019

European Journal of Paediatric Neurology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Safety Outcomesmentioning

confidence: 86%

Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy — A systematic review of the literature using lacosamide as an example

Arzimanoglou

Kalilani

Anamoo

et al. 2019

European Journal of Paediatric Neurology

View full text Add to dashboard Cite

show abstract

“…Refractory seizurePasha et al41 An open label, hospital-based study confirmed the usefulness of lacosamide for adjuvant treatment in patients with refractory partial epilepsy…”

mentioning

confidence: 92%

A Review of the Prevalence, Etiology, Diagnosis, and Management of Pediatric Epilepsies in India

Kalra

Venkataraman

Shah

2022

Journal of Pediatric Neurology

View full text Add to dashboard Cite

Pediatric seizures are one of the most common neurological manifestations seen in pediatrics. Unravelling the etiology, timely and appropriate investigations followed by suitable therapies are essential for improving quality of life. During the pandemic, focused group discussions were conducted among 50 pediatric neurologists across five cities in India to gather insights on treatment practices in pediatric epilepsy and to optimize therapeutic strategies and alternative approaches for rational use of antiepileptic medications. These discussions were mainly aimed at reviewing current literature on prevalence, etiology, diagnosis, and management of epilepsy in children and subsequently rationalizing diagnostic and treatment approaches in routine clinical practice. Epileptic encephalopathies comprise of childhood epilepsy with progressive cerebral dysfunction. Genomics plays a vital role in identifying the underlying genetic associations, empowering precision therapy. Currently, the ketogenic diet has become a well-recognized modality for reducing severity of seizures. To overcome the high incidence of adverse effects due to older antiepileptic drugs, newer drugs are being developed to improve ease of use, diminish drug interactions, decrease adverse effects, and identify drugs with unique mechanisms of action. Common lacunae in practice include information gaps, educating parents, or caregivers about rational drug use and ensuring compliance to antiepileptic medications. This article discussed the consensus clinical viewpoint of expert clinicians, as well as insights on optimized treatment of pediatric epilepsies in both infancy and childhood. It also discusses aspects, like reducing drug burden, emerging therapies in the identification of the genetic basis of epilepsies, and targeted therapy alternatives, for pediatric populations in the Indian scenario.

show abstract

“…It is relatively well-tolerated. Common side effects include dizziness, headache, nausea, vertigo, somnolence, ataxia, and, in a small number of patients, a prolongation of the PR interval and atrioventricular block on electrocardiography [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Adverse Effect of Intravenous Lacosamide in Nonconvulsive Status Epilepticus and Acute Repetitive Seizures in Children

Ngampoopun

Suwanpakdee

Jaisupa

et al. 2018

Neurology Research International

View full text Add to dashboard Cite

Nonconvulsive status epilepticus (NCSE) and acute repetitive seizures (ARS) are associated with significant morbidity and mortality. Due to the lack of randomized-controlled trials of intravenous antiepileptic drugs (AEDs) in these conditions, trials of a new generation of AEDs in this aspect are needed. A prospective interventional study was conducted in children under 18 years of age with NCSE or ARS who either had contraindication to or were refractory to first-line AEDs and received intravenous lacosamide. Demographic data, the efficacy of treatment, and adverse effects were recorded. Eleven patients with a median age of 11 years, predominantly female (72.7%), were enrolled. Average loading dose was 227 mg (8.3 mg/kg/dose) and average daily maintenance dose was 249 mg (4.6 mg/kg/dose). All patients (100%) experienced a reduction in seizure frequency within 24 hours. Eight of eleven patients (72.7%) experienced a reduction in seizure frequency of more than 50% by the end of the study, and one patient became seizure-free. In terms of adverse events, one patient had a bradycardia without prolongation of the PR interval. Interestingly, there was a case of neuronal ceroid lipofuscinosis in which a significant improvement in seizure control was achieved. The results indicate that intravenous lacosamide may be an alternative treatment for NCSE or ARS in children. To our knowledge, this is the first study on the use of intravenous lacosamide in Asian children. This study is registered to Thai Clinical Trials Registry (TCTR) and the trial registration number is TCTR20180508004.

show abstract

Safety of lacosamide in children with refractory partial epilepsy

Abstract: Lacosamide is a well-tolerated newer antiepileptic drug that is effective in refractory partial epilepsy paediatric patients and concurrently improved patient's behaviour.

Cited by 11 publications

References 27 publications

Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy — A systematic review of the literature using lacosamide as an example

Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy — A systematic review of the literature using lacosamide as an example

A Review of the Prevalence, Etiology, Diagnosis, and Management of Pediatric Epilepsies in India

Effectiveness and Adverse Effect of Intravenous Lacosamide in Nonconvulsive Status Epilepticus and Acute Repetitive Seizures in Children

Contact Info

Product

Resources

About